Surface Oncology and Merck to collaborate on immuno-oncology study evaluating SRF617 in combination with KEYTRUDA® (pembrolizumab). Full press release here: https://t.co/Nsx62h611W
Surface Oncology and Merck to collaborate on immuno-oncology study evaluating SRF617 in combination with KEYTRUDA® (pembrolizumab). Full press release here: https://t.co/Nsx62h611W